Structure Therapeutics (GPCR) Rallying on Obesity Drug Data

The capsule-to-tablet PK study was designed to evaluate the tolerability, safety and pharmacokinetics of a new tablet formulation of GSBR-1290 in the given patient population. Data from the capsule-to-tablet PK study showed that treatment with the tablet formulation of GSBR-1290 led to a placebo-adjusted mean weight loss of up to 6.9% at 12 weeks. Image Source: Zacks Investment Research Obesity has become a global health problem as it can cause heart disease, diabetes and stroke, leading to an exponential i ...